Business Context and Reporting Period
Mangoceuticals, Inc. filed this Form 8-K on September 8, 2023, reporting an agreement entered into on September 1, 2023. The company is a Texas corporation whose common stock trades on Nasdaq under the symbol MGRX. The filing concerns a material service agreement and an associated issuance of restricted common stock; it does not report quarterly or annual financial results.
Material Agreement and Consideration
- Mangoceuticals entered into a service agreement with Greentree Financial Group, Inc. after the parties’ prior agreement expired on August 14, 2023.
- Greentree will provide bookkeeping services from October 1, 2023 through September 30, 2024; assist with specified SEC compliance filings and US GAAP disclosures; review accounting documents and systems; coordinate with outside service providers; and prepare the company’s 2022 and 2023 federal tax returns.
- Consideration consists of 75,000 restricted common shares issued upon execution and $40,000 in cash, payable as $20,000 by September 30, 2023 and $20,000 by March 31, 2024.
- The company must also reimburse Greentree’s reasonable out-of-pocket expenses, including specified meeting-related fees and travel expenses.
- The agreement runs through September 30, 2024. Mangoceuticals may terminate with 45 days’ notice, but if it terminates early, the entire cash fee due for the term becomes immediately payable.
- The agreement includes customary indemnification obligations in favor of Greentree and its affiliates.
Revenue, Profit, Cash Flow, Margins, Debt and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, cash balance, liquidity, or other operating or financial performance metrics. The filing text does not provide a clear value for the accounting treatment or fair value of the 75,000 shares.
Material Changes Versus Prior Comparable Period
- The new service agreement replaces an agreement that expired on August 14, 2023.
- The filing does not provide comparative financial information or quantify changes in operating performance, financial position, or liquidity.
Guidance, Outlook, Risks and Unusual Items
- No financial guidance or formal business outlook is provided.
- The agreement creates cash obligations of $40,000, potential reimbursement obligations, and a potential acceleration of the full remaining cash fee upon early termination.
- The issuance of 75,000 restricted shares dilutes existing holders, although the filing does not state the resulting percentage dilution.
- The company’s Chief Financial Officer, Eugene M. Johnston, has served as Greentree’s Audit Manager since February 2015. The filing discloses this relationship but does not characterize it as a related-party transaction or describe any specific conflict-management procedures.
- The shares were issued without registration under Section 4(a)(2) and/or Rule 506 of Regulation D. They are restricted, subject to transfer limitations, and bear a restrictive legend.
Facts Investors Should Verify
- Review Exhibit 10.1 for the complete service terms, termination provisions, indemnification language, and expense reimbursement obligations.
- Confirm issuance of the 75,000 restricted shares and determine their accounting value and dilution impact.
- Verify payment of the $20,000 installments and any additional reimbursable expenses.
- Assess the significance of the CFO’s ongoing role with Greentree and whether subsequent filings provide additional related-party or independence disclosures.
- Review subsequent SEC filings for the company’s financial condition, liquidity, accounting compliance, and performance of the services.